Engineers Gate Manager’s Structure Therapeutics GPCR Stock Holding History

Engineers Gate Manager’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-9,593	Closed	-$269K	–	2264
2025 Q3	$269K	Sell	9,593 -6,269	-40%	-$125K	﹤0.01%	1790
2025 Q2	$329K	Buy	+15,862	New	+$349K	﹤0.01%	1674
2025 Q1	–	Sell	-16,880	Closed	-$458K	–	2308
2024 Q4	$458K	Sell	16,880 -8,595	-34%	-$305K	0.01%	1487
2024 Q3	$1.12M	Sell	25,475 -18,006	-41%	-$696K	0.02%	923
2024 Q2	$1.71M	Buy	+43,481	New	+$1.79M	0.04%	630
2024 Q1	–	Sell	-29,414	Closed	-$1.2M	–	2060
2023 Q4	$1.2M	Buy	+29,414	New	+$1.69M	0.03%	708

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Engineers Gate Manager's GPCR Position: Q4 2025 in Review

Engineers Gate Manager sold out of Structure Therapeutics (GPCR) in Q4 2025, closing a stake of 9,593 shares — an estimated $269K sold.

Engineers Gate Manager first reported a position in GPCR in Q4 2023 and held it in 6 quarters. The position peaked at $1.71M in Q2 2024. 197 funds tracked by Wall St. Rank hold GPCR as of Q4 2025.

Engineers Gate Manager reported no remaining Structure Therapeutics position as of Q4 2025 after selling out during the quarter.
Engineers Gate Manager sold 9,593 Structure Therapeutics shares in Q4 2025, an estimated $269K.
Engineers Gate Manager first reported a position in Structure Therapeutics in Q4 2023 and held it in 6 quarters.
Engineers Gate Manager's Structure Therapeutics position peaked at $1.71M in Q2 2024.
197 funds tracked by Wall St. Rank held Structure Therapeutics as of Q4 2025.

Based on Engineers Gate Manager's 13F filing for Q4 2025, filed 17 Feb 2026.